Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;136(4):603-10.
doi: 10.1007/s00432-009-0698-x. Epub 2009 Oct 9.

Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling

Affiliations

Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling

Chunyan Sun et al. J Cancer Res Clin Oncol. 2010 Apr.

Abstract

Purpose: Pancreatic cancer has been a serious disease worldwide for its high mortality. Cucurbitacin E is a member of triterpenoid family isolated from plants showing antiproliferative activity on various cancer cells. In this study, we have explored whether cucurbitacin E also has an anti-tumor effect on pancreatic cancer cells.

Methods: Human pancreatic cancer cells PANC-1 were used to explore the effect and possible mechanisms of cucurbitacin E on cell cycle progression, apoptosis and proliferation.

Results: Cucurbitacin E has inhibited the growth of PANC-1 cells in a dose- and time-dependent manner, and has caused accumulation of cells at the G(2)/M phase as well as apoptosis. Western blotting also showed that cucurbitacin E treatment can inhibit STAT3 phosphorylation while upregulate p53 expression.

Conclusions: Our results suggested that cucurbitacin E may be an effective regimen for the chemotherapy of pancreatic cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Dose- and time-dependent effect of CuE on the viability of PANC-1 cells. PANC-1 cells at 5 × 103 cells/well were cultured in RPMI 1640–10% FBS with CuE (0.01, 0.1, 1, 10 and 100 μM) for 24, 48 and 72 h. Cell viability was determined daily with a MTT assay
Fig. 2
Fig. 2
Effect of CuE on cell cycle distribution. (a) PANC-1 cells (1 × 106) were treated with 1 μM of CuE and analyzed at (a) 0, (b) 12 and (c) 24 h by DNA flow cytometry. (b) PANC-1 cells (1 × 106) were treated with 0, 0.1, 1 μM of CuE and analyzed at 24 h by DNA flow cytometry. * P<0.05 compared with control
Fig. 3
Fig. 3
Apoptosis shown by Hoechst 33258 staining (400×). (a) PANC-1 cells treated with (a) 0, (b) 0.01, (c) 0.1 and (d) 1 μM of CuE for 24 h. (b) PANC-1 cells treated with 1 μM of CuE for (a) 0, (b) 12 and (c) 24 h
Fig. 4
Fig. 4
Apoptosis measured by Annexin V-FITC/PI staining. PANC-1 cells were treated with 0, 0.1, 1 and 10 μM of CuE for 24 h, stained with Annexin V-FITC and PI, and analyzed with flow cytometry. The horizontal and vertical axes represent labeling with Annexin V-FITC and PI, respectively. LR represents early apoptotic cells (positive for Annexin V only), UR represents late apoptotic cells (positive for both Annexin V and PI), LL represents live cells
Fig. 5
Fig. 5
Western blot analysis of p-STAT3 and p53 proteins. PANC-1 cells were treated with 0, 0.01, 0.1, 1 and 10 μM of CuE for 24 h. Cells were then harvested and processed for western blotting as described in “Material and methods”. β-actin was used as the internal control

References

    1. Al Zaid Siddiquee K, Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18:254–267 - PMC - PubMed
    1. Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076–1082 - PMC - PubMed
    1. Bartz C, Ziske C, Wiedenmann B, Moelling K (1996) P53 tumor suppressor gene expression in pancreatic neuroendocrine tumour cells. Gut 38:403–409 - PMC - PubMed
    1. Brell JM, Matin K, Evans T, Volkin RL, Kiefer GJ, Schlesselman JJ, Dranko S, Rath L, Schmotzer A, Lenzner D, Ramanathan RK (2009) Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 76:270–274 - PubMed
    1. Butz J, Wickstrom E, Edwards J (2003) Characterization of mutation and loss of heterozygosity of 53 and K-ras-2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnol 3:11 - PMC - PubMed

Publication types